Evidence map›Paper›PMID 24221642›Full record

ArticleJournal of neurology2014

Pharmacological therapies in post stroke recovery: recommendations for future clinical trials.

F Chollet, S C Cramer, C Stinear, L J Kappelle, J C Baron, C Weiller, P Azouvi, M Hommel, U Sabatini, T Moulin and 4 more

Abstract read
PubMed Publisher
In one paragraph

Article in Journal of neurology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed, 1 pooled it
5.4field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

23 citing papers in PubMed, 1 synthesis or guideline pooled it, 43 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Trial
  4. Review
  5. Review
  6. Article
  7. Review
  8. Article
  9. Review
  10. Review
  11. Observational
  12. Review
  13. Review
  14. Review
  15. Article
  16. Review
  17. Review
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 14 institutions in 7 countries.

F CholletUPS, Imagerie Cérébrale et Handicaps Neurologiques UMR 825, Centre Hospitalier Universitaire de Toulouse, Université de Toulouse, Toulouse, France, francois.chollet@inserm.fr.
S C Cramer
C Stinear
L J Kappelle
J C Baron
C Weiller
P Azouvi
M Hommel
U Sabatini
T Moulin
J Tardy
M Valenti
S Montgomery
H Adams
Centre Hospitalier Universitaire de Besançon · FRCentre Hospitalier Universitaire de Grenoble · FRClinique des Cèdres · FRDélégation Paris 5 · FRFondazione Santa Lucia · ITImperial College London · GBUniversité de Versailles Saint-Quentin-en-Yvelines · FRUniversité Toulouse III - Paul Sabatier · FRUniversity Medical Center Utrecht · NLUniversity of Auckland · NZUniversity of California, Irvine · USUniversity of Freiburg · DEUniversity of Iowa · USUniversity of L'Aquila · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Stroke is a leading cause of serious long-term disability in adults and is the second leading cause of death worldwide. Early reperfusion and neuroprotection techniques have been the focus of much effort with the aim of very acute treatment of the stroke. Targeting different mechanisms, pharmacological therapies have the potential to reduce disability in a large fraction of patients who survive the acute stroke. The brain's capacity to reorganize after stroke through plasticity mechanisms can be modulated by pharmacological agents. A number of therapeutic interventions are under study, including small molecules, growth factors, and monoclonal antibodies. Recently it has been shown that the SSRI fluoxetine improved motor deficit in patients with ischaemic stroke and hemiplegia which appeared to be independent of the presence of depression. In this context, it is of major importance to support innovative research in order to promote the emergence of new pharmacological treatments targeting neurological recovery after stroke, as opposed to acute de-occlusion and neuroprotection. This paper is the work of a group of 14 scientists with aim of (1) addressing key areas of the basic and clinical aspects of human brain plasticity after stroke and potential pharmacological targets for recovery, (2) asking questions about the most appropriate characteristics of clinical trials testing drugs in post stroke recovery and (3) proposing recommendations for future clinical trials.

Indexed as

Clinical Trials as TopicHumansNeuroprotective AgentsRecovery of FunctionStrokeNeuroprotective Agents

Identifiers

PMID24221642
OpenAlexW1987797267

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.